REG - Synairgen plc - Result of General Meeting and Total Voting Rights

SynairgenAnnouncement

16/01/2025 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250116:nRSP6572Ta&default-theme=true

RNS Number : 6572T  Synairgen plc  16 January 2025

 

Synairgen plc

('Synairgen' or the 'Company')

Result of General Meeting and Total Voting Rights

 

Southampton, UK - 16 January 2025: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces
that, at the General Meeting held earlier today, all resolutions as set out in
the Circular dated 20 December 2024, were duly passed by shareholders on a
poll.

A summary of the votes received for the General Meeting will be made available
shortly on the Company's website at
https://www.synairgen.com/investors/aim-rule-26
(https://www.synairgen.com/investors/aim-rule-26) .

Accordingly, the Company has raised total gross proceeds of £18 million from
the Subscription by TFG Asset Management (on behalf of the Relevant Funds).

Application has been made for a total of 900,000,000 New Ordinary Shares to be
issued pursuant to the Subscription, to be admitted to trading on AIM.  It is
expected that Admission and dealings in the 900,000,000 New Ordinary Shares
will commence at 8.00 a.m. on 17 January 2025.

Following Admission, the Company's issued ordinary share capital will comprise
1,102,660,697 Ordinary Shares, none of which are held in treasury. The above
figure of 1,102,660,697 may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the voting rights of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

As detailed in the Results of Non-Underwritten Fundraising announcement on 15
January 2025, as the Minimum Fundraising Condition was not met the Company
intends to apply for the cancellation of its Ordinary Shares from trading on
AIM ("Cancellation"). A separate announcement will be made in this regard and
a circular will be posted to Shareholders in due course which will contain
details of the proposed Cancellation.

Following the conclusion of the General Meeting, Martin Murphy has been
appointed as an independent Non-Executive Director of the Company. See
separate announcement issued today announcing Martin's appointment.

This announcement should be read in conjunction with the full text of the
Circular posted to Shareholders on 20 December 2024, copies of which are
available on the Company's website. The same definitions apply throughout this
announcement as are applied in the Circular.

For further enquiries, please contact:

 Synairgen plc                                                      + 44 (0)23 8051 2800
 Media@synairgen.com (mailto:Media@synairgen.com)
 Cavendish Capital Markets Limited -                                + 44 (0)20 7220 0500

Nominated Adviser, joint broker and sole bookrunner
 Geoff Nash/Camilla Hume/Trisyia Jamaludin
 ICR Healthcare (Financial Media and Investor Relations)            +44 (0)20 3709 5700
 Mary-Jane Elliott/Namrata Taak/Lucy Featherstone
 synairgen@icrhealthcare.com (mailto:synairgen@icrhealthcare.com)

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com (http://www.synairgen.com)

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the retained EU law version of the
Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMPKABNPBKDNDD